Table 2 Risk stratification for cause-specific deaths over 10 years derived from the single nucleotide polymorphisms (SNPs) with the highest and lowest hazard ratios (HR) with an association stronger than the predetermined threshold of p < 0.01, unadjusted for baseline risks or multiple testing
From: Common genetic variants do not predict recurrent events in coronary heart disease patients
Outcome variable | SNP number | HR* 95% CI | p Value | Genotype | Gene | Chromosome | Location | Function |
|---|---|---|---|---|---|---|---|---|
Total deaths | rs2247056 | 1.15 (1.07, 1.25) | 0.0003 | CT | HLA-C/HLA-B | 6 | 31,265,490 | Blood lipid levels |
rs2131925 | 1.13 (1.05, 1.22) | 0.0019 | GT | DOCK7 | 1 | 63,025,942 | Blood lipid levels | |
rs10455872 | 1.19 (1.06, 1.34) | 0.0038 | AG | LPA | 6 | 161,010,118 | Blood Lp (a) level | |
rs7298565 | 1.10 (1.03, 1.18) | 0.0052 | AG | UBE3B | 12 | 109,937,534 | DNA synthesis and cell proliferation | |
rs7134594 | 0.91 (0.85, 0.97) | 0.0060 | CT | MMAB | 12 | 110,000,193 | Vitamin B12 metabolism | |
rs16868846 | 0.82 (0.71, 0.95) | 0.0068 | CG | KCNK5 | 6 | 39,207,558 | Potassium channel control | |
rs2252641 | 1.10 (1.03, 1.18) | 0.0080 | AG | PABPCP2 | 2 | 145,801,461 | CHD | |
CVD deaths | rs10455872 | 1.28 (1.10, 1.49) | 0.0015 | AG | LPA | 6 | 161,010,118 | Blood Lp (a) level; CHD |
CHD deaths | rs10455872 | 1.33 (1.13, 1.57) | 0.0008 | AG | LPA | 6 | 161,010,118 | Lipoprotein (a) and LpPLA2 levels |
Cancer deaths | rs2131925 | 1.28 (1.09, 1.50) | 0.0022 | GT | DOCK7 | 1 | 63,025,942 | Blood lipid levels |
rs11556924 | 0.80 (0.68, 0.93) | 0.0037 | CT | ZC3HC1 | 7 | 129,663,496 | CHD | |
rs2247056 | 1.25 (1.07, 1.46) | 0.0047 | CT | HLA-C/HLA-B | 6 | 31,265,490 | Blood lipid levels |